Works matching IS 11738804 AND DT 2019 AND VI 33 AND IP 4

Results: 9

Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy.

Published in:

BioDrugs, 2019, v. 33, n. 4, p. 345, doi. 10.1007/s40259-019-00365-2

By:

Ingrasciotta, Ylenia;
Sultana, Janet;
Kirchmayer, Ursula;
Trifirò, Gianluca

Publication type:

Article

Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Review of Current Status.

Published in:

BioDrugs, 2019, v. 33, n. 4, p. 401, doi. 10.1007/s40259-019-00364-3

By:

Tyndall, Alan

Publication type:

Article

Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment.

Published in:

BioDrugs, 2019, v. 33, n. 4, p. 411, doi. 10.1007/s40259-019-00362-5

By:

Lee, Jae Hee;
Paek, Kyungyeol;
Moon, Jae Hyon;
Ham, Sunyoung;
Song, Jinsu;
Kim, Seokkyun

Publication type:

Article

Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.

Published in:

BioDrugs, 2019, v. 33, n. 4, p. 391, doi. 10.1007/s40259-019-00361-6

By:

Reis, Joel;
Vender, Ron;
Torres, Tiago

Publication type:

Article

Biosimilars: A Value Proposition.

Published in:

BioDrugs, 2019, v. 33, n. 4, p. 353, doi. 10.1007/s40259-019-00360-7

By:

de Mora, Fernando

Publication type:

Article

Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.

Published in:

BioDrugs, 2019, v. 33, n. 4, p. 423, doi. 10.1007/s40259-019-00359-0

By:

Lee, Seung-Mi;
Jung, Jae-Ho;
Suh, David;
Jung, Yu-Seon;
Yoo, Seung-Lai;
Kim, Dong-Won;
Kim, Ji-An;
Suh, Dong-Churl

Publication type:

Article

Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Published in:

BioDrugs, 2019, v. 33, n. 4, p. 357, doi. 10.1007/s40259-019-00358-1

By:

Yang, Jichun;
Yu, Shuqing;
Yang, Zhirong;
Yan, Yusong;
Chen, Yao;
Zeng, Hongmei;
Ma, Fei;
Shi, Yanxia;
Shi, Yehui;
Zhang, Zilu;
Sun, Feng

Publication type:

Article

Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?

Published in:

BioDrugs, 2019, v. 33, n. 4, p. 437, doi. 10.1007/s40259-019-00357-2

By:

Tu, Chien-Lung;
Wang, Yi-Lin;
Hu, Teh-Min;
Hsu, Li-Feng

Publication type:

Article

Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis.

Published in:

BioDrugs, 2019, v. 33, n. 4, p. 373, doi. 10.1007/s40259-019-00356-3

By:

Yang, Jichun;
Yu, Shuqing;
Yang, Zhirong;
Yan, Yusong;
Chen, Yao;
Zeng, Hongmei;
Ma, Fei;
Shi, Yanxia;
Shi, Yehui;
Zhang, Zilu;
Sun, Feng

Publication type:

Article